Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

del(8p) and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia.

Leukemia - 1 Nov 2023

Jondreville Ludovic, Dehgane Lea, Doualle Cecile, Smagghe Luce, Grange Beatrice, Davi Frederic, Lerner Leticia K, Garnier Delphine, Bravetti Clotilde, Tournilhac Olivier, Roos-Weil Damien, Boubaya Marouane, Chapiro Elise, Susin Santos A, Nguyen-Khac Florence

Abstract excerpt

Chronic lymphocytic leukemia (CLL) is a heterogeneous disease, the prognosis of which varies according to the cytogenetic group. We characterized a rare chromosomal abnormality (del(8p), deletion of the short arm of chromosome 8) in the context of CLL. By comparing the largest cohort of del(8p) CLL to date (n = 57) with a non-del(8p) cohort (n = 155), del(8p) was significantly associated with a poor prognosis, a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosome Aberrations
Share to Leukemia, Lymphocytic, Chronic, B-Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Prognosis

Share to Receptors, TNF-Related Apoptosis-Inducing Ligand

Share to Vidarabine

Source

Identifiers

PMID: 37752286
DOI: 10.1038/s41375-023-02035-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

del(8p) and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia.PMID 37752286Read ↗

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.Semantic proximity Read ↗

Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemiaSemantic proximity Read ↗

Recent therapeutic advances in chronic lymphocytic leukemiaSemantic proximity Read ↗

Tumor suppressors in follicular lymphoma.Semantic proximity Read ↗

TRAF3 alterations are frequent in del-3'IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features.Semantic proximity Read ↗

17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach.Semantic proximity Read ↗

Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia.Semantic proximity Read ↗

Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia.Semantic proximity Read ↗

Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.Semantic proximity Read ↗

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.Semantic proximity Read ↗

Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression responseSemantic proximity Read ↗

IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.